Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02002884
Other study ID # MRZ60201_3072_1
Secondary ID 2012-005496-14
Status Completed
Phase Phase 3
First received
Last updated
Start date March 28, 2014
Est. completion date August 28, 2018

Study information

Verified date July 2020
Source Merz Pharmaceuticals GmbH
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine whether injections of Botulinum toxin type A into muscles of one or both arms alone or in combination with injections into one or both legs are effective and safe in treating children/adolescents (age 2-17 years) with increased muscle tension/uncontrollable muscle stiffness (spasticity) due to cerebral palsy.


Recruitment information / eligibility

Status Completed
Enrollment 351
Est. completion date August 28, 2018
Est. primary completion date July 4, 2017
Accepts healthy volunteers No
Gender All
Age group 2 Years to 17 Years
Eligibility Inclusion Criteria: - Female or male subject of 2 to 17 years of age (inclusive). - Uni- or bilateral Cerebral Palsy (CP) with clinical need for injections with NT 201 for the treatment of upper limb (UL) spasticity at least unilaterally. - Ashworth Scale (AS) score in the main clinical target patterns in this study: 1. Flexed elbow: AS=2 in elbow flexors (at least unilaterally). and/or 2. Flexed Wrist: AS=2 in wrist flexors (at least unilaterally). - Clinical need according to the judgment of the investigator in one out of five treatment combinations (A-E, as shown below). AS score must be =2 for each target pattern chosen for injection at the Baseline Injection Visit V2. A. UL(s) treatment only (GMFCS I-V): A1) Unilateral treatment of UL spasticity with 8 U/kg BW NT 201 (maximum of 200 U) for: 1. At least one of the main clinical target patterns flexed elbow (4 U/kg BW) and/or flexed wrist (2 U/kg BW). and 2. Additional clinical patterns in the same limb (i.e., clenched fist, thumb in palm, and/or pronated forearm) with the remaining units until maximum dose of 8 U/kg BW (maximum of 200 U) for treatment of a single UL is reached. or A2) Bilateral treatment of UL spasticity with equal doses of 8 U/kg BW NT 201 (maximum of 200 U) to each UL. Dose per UL must be distributed between: 1. At least one of the main clinical target patterns flexed elbow (4 U/kg BW) and/or flexed wrist (2 U/kg BW). and 2. Additional clinical patterns in the same limb (i.e., clenched fist, thumb in palm, and/or pronated forearm) with the remaining units until maximum dose of 8 U/kg BW (maximum of 200 U) for treatment of a single UL is reached. B. Unilateral UL and unilateral lower limb (LL) treatment (GMFCS I-V): B1) Unilateral treatment of UL spasticity with 8 U/kg BW NT 201 (maximum of 200 U) for: 1. At least one of the main clinical target patterns flexed elbow (4 U/kg BW) and/or flexed wrist (2 U/kg BW). and 2. Additional clinical patterns in the same limb (i.e., clenched fist, thumb in palm, and/or pronated forearm) with the remaining units until maximum dose of 8 U/kg BW (maximum of 200 U) for treatment of a single UL is reached. plus B2) Ipsilateral unilateral treatment of LL spasticity with 8 U/kg BW NT 201 (maximum of 200 U). Dose to LL must be distributed to at least one of clinical target patterns pes equinus, flexed knee, adducted thigh, and extended great toe as clinically needed. C. Unilateral UL and bilateral LL treatment (GMFCS I-III) C1) Unilateral treatment of UL spasticity with 8 U/kg BW NT 201 (maximum of 200 U) for: 1. At least one of the main clinical target patterns flexed elbow (4 U/kg BW) and/or flexed wrist (2 U/kg BW). and 2. Additional clinical patterns in the same limb (i.e., clenched fist, thumb in palm, and/or pronated forearm) with the remaining units until maximum dose of 8 U/kg BW (maximum of 200 U) for treatment of a single UL is reached. plus C2) Bilateral treatment of LL spasticity with 12 U/kg BW (maximum of 300 U). Dose must be distributed into at least one of clinical target patterns pes equinus, flexed knee, adducted thigh, and extended great toe, on each side. Dose distribution may vary between sides as clinically needed. D. Unilateral UL and bilateral LL treatment (GMFCS IV and V) D1) Unilateral treatment of UL spasticity with 8 U/kg BW NT 201 (maximum of 200 U) for: 1. At least one of the main clinical target patterns flexed elbow (4 U/kg BW) and/or flexed wrist (2 U/kg BW). and 2. Additional clinical patterns in the same limb (i.e., clenched fist, thumb in palm, and/or pronated forearm) with the remaining units until maximum dose of 8 U/kg BW (maximum of 200 U) for treatment of a single UL is reached. plus D2) Bilateral treatment of LL spasticity with 8 U/kg BW (maximum of 200 U). Dose must be distributed into at least one of clinical target patterns pes equinus, flexed knee, adducted thigh, and extended great toe, on each side. Dose distribution may vary between sides as clinically needed. E. Bilateral UL treatment and bilateral LL treatment (GMFCS I-III) E1) Bilateral treatment of UL spasticity with equal doses of 8 U/kg BW NT 201 (maximum of 200 U) to each UL. Dose per UL must be distributed between 1. At least one of the main clinical target patterns flexed elbow (4 U/kg BW) and/or flexed wrist (2 U/kg BW) and 2. Additional clinical patterns in the same limb (i.e., clenched fist, thumb in palm, and/or pronated forearm) with the remaining units until maximum dose of 8 U/kg BW (maximum of 200 U) for treatment of a single UL is reached. plus E2) Bilateral treatment of LL spasticity with 4 U/kg BW (maximum of 100 U). Dose must be distributed into at least one of clinical target patterns pes equinus, flexed knee, adducted thigh, and extended great toe, on each side. Dose distribution may vary between sides as clinically needed. Exclusion Criteria: Pre-treated (non-naïve) subjects must not have received BoNT treatment within the last 14 weeks prior to Screening Visit (V1) in any indication.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
IncobotulinumtoxinA (8 Units per kg body weight)
Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Mode of administration: intramuscular injection into spastic muscles.
IncobotulinumtoxinA (6 Units per kg body weight)
Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Mode of administration: intramuscular injection into spastic muscles.
IncobotulinumtoxinA (2 Units per kg body weight)
Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Mode of administration: intramuscular injection into spastic muscles.

Locations

Country Name City State
Argentina Merz Investigational Site #054005 Caba
Argentina Merz Investigational Site #054010 Godoy Cruz Provincia De Mendoza
Mexico Merz Investigational Site #052023 Aguascalientes
Mexico Merz Investigational Site #052003 Guadalajara
Mexico Merz Investigational Site #052022 Mexico City
Mexico Merz Investigational Site #052024 Mexico City
Mexico Merz Investigational Site #052027 Monterrey
Mexico Merz Investigational Site #052028 Monterrey
Mexico Merz Investigational Site #052026 Zapopan
Poland Merz Investigational Site #048089 Bialystok
Poland Merz Investigational Site #048063 Gdansk
Poland Merz Investigational Site #048059 Krakow
Poland Merz Investigational Site #048084 Lublin
Poland Merz Investigational Site #048094 Poznan
Poland Merz Investigational Site #048075 Sandomierz
Poland Merz Investigational Site #048060 Wiazowna
Russian Federation Merz Investigational Site #007014 Kazan
Russian Federation Merz Investigational Site #007015 Khabarovsk
Russian Federation Merz Investigational Site #007018 Novosibirsk
Russian Federation Merz Investigational Site #007298 Saint Petersburg
Russian Federation Merz Investigational Site #007013 Smolensk
Russian Federation Merz Investigational Site #007019 Stavropol
Ukraine Merz Investigational Site #380001 Dnipropetrovsk
Ukraine Merz Investigational Site #380005 Kharkiv
Ukraine Merz Investigational Site #380002 Kyiv
Ukraine Merz Investigational Site #380003 Odessa
United States Merz Investigational Site #001186 Chicago Illinois
United States Merz Investigational Site #001283 Columbia Missouri
United States Merz Investigational Site #001286 Gulf Breeze Florida
United States Merz Investigational Site #001284 Loxahatchee Groves Florida
United States Merz Investigational Site No. #001302 Royal Oak Michigan
United States Merz Investigational Site #001285 Savannah Georgia

Sponsors (1)

Lead Sponsor Collaborator
Merz Pharmaceuticals GmbH

Countries where clinical trial is conducted

United States,  Argentina,  Mexico,  Poland,  Russian Federation,  Ukraine, 

References & Publications (1)

Dabrowski E, Chambers HG, Gaebler-Spira D, Banach M, Kanovský P, Dersch H, Althaus M, Geister TL, Heinen F. IncobotulinumtoxinA Efficacy/Safety in Upper-Limb Spasticity in Pediatric Cerebral Palsy: Randomized Controlled Trial. Pediatr Neurol. 2021 May 21; — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary MP: Change From Baseline in Ashworth Scale (AS) in UL Primary Clinical Target Pattern at Week 4 The AS categorizes severity of spasticity by judging resistance to passive movement. Spasticity was assessed by using the 5-point AS with:0 (no increase in tone); 1 (slight increase in tone giving a "catch" when the limb was moved in flexion or extension); 2 (more marked increase in tone, but limb easily flexed); 3 (considerable increase in tone -passive movements difficult); 4 (limb rigid in flexion or extension). Values represent least square (LS) mean differences between baseline and Week 4 resulting from Mixed Model Repeated Measurement (MMRM) models comparing high versus low and in a second step mid versus low dose groups, respectively. Values for the low group may differ slightly depending on the comparison and are therefore provided separately for each comparison. Baseline and Week 4
Primary Co-primary Variable MP: Investigator's Global Impression of Change Scale (GICS) at Week 4 The GICS was used to measure independently the investigator's impression of change due to treatment. The response option was a common 7-point Likert scale, that ranges from +3 (very much improved); +2 (much improved); +1 (minimally improved); 0 (no change); -1 (minimally worse); -2 (much worse); -3 (very much worse). Values represent LS mean differences between baseline and Week 4 resulting from ANCOVA models comparing high versus low and in a second step mid versus low dose groups, respectively. Values for the low group may differ slightly depending on the comparison and are therefore provided separately for each comparison. Week 4
Secondary MP: Change From Baseline in AS Score of the Other Treated UL Main Clinical Target Pattern at Week 4 The AS categorizes the severity of spasticity by judging resistance to passive movement. Spasticity was assessed by 5-point scale at visits, where: 0 (no increase in tone); 1(slight increase in tone giving a "catch" when the limb was moved in flexion or extension); 2(more marked increase in tone, but limb easily flexed); 3(considerable increase in tone - passive movements difficult); 4(limb rigid in flexion or extension). Values represent LS mean differences between baseline and Week 4 resulting from MMRM models comparing high versus low and in a second step mid versus low dose groups, respectively. Values for the low group may differ slightly depending on the comparison and are therefore provided separately for each comparison. Baseline and Week 4
Secondary MP: Change From Baseline in AS Score in UL Treated Clenched Fist With Flexed Wrist at Week 4 The AS categorizes the severity of spasticity by judging resistance to passive movement. Spasticity was assessed by 5-point scale at visits, where: 0 (no increase in tone); 1(slight increase in tone giving a "catch" when the limb was moved in flexion or extension); 2(more marked increase in tone, but limb easily flexed); 3(considerable increase in tone - passive movements difficult); 4(limb rigid in flexion or extension). Values represent LS mean differences between baseline and Week 4 resulting from MMRM models comparing high versus low and in a second step mid versus low dose groups, respectively. Values for the low group may differ slightly depending on the comparison and are therefore provided separately for each comparison. Baseline and Week 4
Secondary MP: Change From Baseline in AS Score for Each Treated Clinical Pattern of the UL at Week 4 The AS categorizes the severity of spasticity by judging resistance to passive movement. Spasticity was assessed by 5-point scale at visits, where: 0 (no increase in tone); 1(slight increase in tone giving a "catch" when the limb was moved in flexion or extension); 2(more marked increase in tone, but limb easily flexed); 3(considerable increase in tone - passive movements difficult); 4(limb rigid in flexion or extension). Values represent LS mean differences between baseline and Week 4 resulting from MMRM models comparing high versus low and in a second step mid versus low dose groups, respectively. Values for the low group may differ slightly depending on the comparison and are therefore provided separately for each comparison. Baseline up to Week 4
Secondary MP: Change From Baseline in Scores of Pain Intensity (From Participants) and Pain Frequency (From Parent/Caregiver) Assessed With 'Questionnaire on Pain Caused by Spasticity (QPS)' Pain intensity (from participants) and pain frequency (from parent/caregiver) to be assessed with QPS. The QPS Total Score for pain intensity ranges from 0 ('No Hurt') to 10 ('Hurt Worst'). The QPS Total Score for the observed pain frequency ranges from 0 (Never) to 4 (Always). Values represent LS mean differences between baseline and Week 4 resulting from MMRM models comparing high versus low and in a second step mid versus low dose groups, respectively. Values for the low group may differ slightly depending on the comparison and are therefore provided separately for each comparison. P/C = Parent/Caregiver. Baseline, Weeks 4, 8, and 14
Secondary MP: Child's/Adolescent's, and Parent's/Caregiver's GICS in UL at Week 4 The GICS was used to measure independently the child's/adolescent's, and parent's or caregiver's impression of change due to treatment. The response option was a common 7-point Likert scale, that ranges from: +3(very much improved); +2(much improved); +1(minimally improved); 0(no change); -1(minimally worse); -2(much worse); -3(very much worse). Values represent LS mean differences between baseline and Week 4 resulting from ANCOVA models comparing high versus low and in a second step mid versus low dose groups, respectively. Values for the low group may differ slightly depending on the comparison and are therefore provided separately for each comparison. Week 4
Secondary Number of Participants With Occurrence of Treatment Emergent Adverse Events (TEAEs) Overall and Per Treatment Cycle Baseline up to Week 66
Secondary Number of Participants With Occurrence of TEAEs of Special Interest (TEAESIs) Overall and Per Treatment Cycle Baseline up to Week 66
Secondary Number of Participants With Occurrence of Serious TEAEs (TESAEs) Overall and Per Treatment Cycle Baseline up to Week 66
Secondary Number of Participants With Occurrence of TEAEs Related to Treatment Overall and Per Treatment Cycle Baseline up to Week 66
Secondary Number of Participants With Occurrence of TEAEs by Worst Intensity Overall and Per Treatment Cycle Baseline up to Week 66
Secondary Number of Participants With Occurrence of TEAEs by Worst Causal Relationship Overall and Per Treatment Cycle Baseline up to Week 66
Secondary Number of Participants With Occurrence of TEAEs by Final Outcome Overall and Per Treatment Cycle Baseline up to Week 66
Secondary Number of Participants With Occurrence of TEAEs Leading to Discontinuation Overall and Per Treatment Cycle Baseline up to Week 66
See also
  Status Clinical Trial Phase
Recruiting NCT05317234 - Genetic Predisposition in Cerebral Palsy N/A
Recruiting NCT05576948 - Natural History of Cerebral Palsy Prospective Study
Completed NCT04119063 - Evaluating Wearable Robotic Assistance on Gait Early Phase 1
Completed NCT03264339 - The Small Step Program - Early Intervention for Children With High Risk of Developing Cerebral Palsy N/A
Completed NCT05551364 - Usability and Effectiveness of the ATLAS2030 Exoskeleton in Children With Cerebral Palsy N/A
Completed NCT03902886 - Independent Walking Onset of Children With Cerebral Palsy
Recruiting NCT05571033 - Operant Conditioning of the Soleus Stretch Reflex in Adults With Cerebral Palsy N/A
Not yet recruiting NCT04081675 - Compliance in Children With Cerebral Palsy Supplied With AFOs
Completed NCT02167022 - Intense Physiotherapies to Improve Function in Young Children With Cerebral Palsy N/A
Completed NCT04012125 - The Effect of Flexible Thoracolumbar Brace on Scoliosis in Cerebral Palsy N/A
Enrolling by invitation NCT05619211 - Piloting Movement-to-Music With Arm-based Sprint-Intensity Interval Training Among Children With Physical Disabilities Phase 1
Completed NCT04489498 - Comparison of Somatometric Characteristics Between Cerebral Palsy and Normal Children, Cross-sectional, Multi Center Study
Completed NCT03677193 - Biofeedback-enhanced Interactive Computer-play for Youth With Cerebral Palsy N/A
Recruiting NCT06450158 - Robot-assisted Training in Children With CP N/A
Completed NCT04093180 - Intensive Neurorehabilitation for Cerebral Palsy N/A
Completed NCT02909127 - The Pediatric Eating Assessment Tool
Not yet recruiting NCT06377982 - Human Umbilical Cord Blood Infusion in Patients With Cerebral Palsy Phase 1
Not yet recruiting NCT06007885 - Examining Capacity Building of Youth With Physical Disabilities to Pursue Participation Following the PREP Intervention. N/A
Not yet recruiting NCT03183427 - Corpus Callosum Size in Patients With Pineal Cyst N/A
Active, not recruiting NCT03078621 - Bone Marrow-Derived Stem Cell Transplantation for the Treatment of Cerebral Palsy Phase 1/Phase 2